A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors
Authors:Kieran Mark W (United States, Americas)Chi Susan (United States, Americas)Goldman Stewart (United States, Americas)Onar Thomas Arzu (United States, Americas)Poussaint Tina Young (United States, Americas)
+ 12 more
Vajapeyam Sridhar (United States, Americas)Fahey Frederic (United States, Americas)Wu Shengjie (China, Asia)Turner David C (United States, Americas)Stewart Clinton F (United States, Americas)Moses Marsha (United States, Americas)Packer Roger J (United States, Americas)Jakacki Regina (United States, Americas)Banerjee Anu (United States, Americas)Boyett James M (United States, Americas)Fouladi Maryam (United States, Americas)Kun Larry (United States, Americas)
Source: Childs Nerv Syst 31, 1433–1445 (2015).
Date: July 19, 2015Please create a free account or log in to view this item
Registration is free, quick and easy. Simply register and complete your profile to get access. If you already have an account with the ISPN Library or ISPN Guide, login below.
Create an account
Login
Register
Log in using your ISPN Guide or ISPN Library credentials
Not yet registered? Join now









